Royal Bank of Canada reissued their outperform rating on shares of Moderna (NASDAQ:MRNA – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has a $125.00 price objective on the stock. Several other research analysts have also recently issued reports on MRNA. JPMorgan Chase & Co. decreased […]